Clinical Trials Logo

Clinical Trial Summary

ReliaSeal is a clinical trial designed to evaluate safety and efficacy of use of MYNX CONTROLâ„¢ Venous Vascular Closure Device 6F-12F vs. manual compression to seal femoral access sites in patients who have undergone endovascular procedures utilizing up to 12F procedural sheaths in one or both limbs.


Clinical Trial Description

ReliaSeal is a multicenter, prospective, randomized, controlled, open label clinical trial designed to evaluate safety and efficacy of use of MYNX CONTROLâ„¢ Venous Vascular Closure Device 6F-12F vs. manual compression to seal femoral access sites in patients who have undergone endovascular procedures utilizing up to 12F procedural sheaths in one or both limbs. The study is planned to enroll 204 patients with an additional group of patients to be part of the initial roll-in phase. Up to two (2) roll-in patients per physician will be allowed. All patients who sign the informed consent and randomized to either treatment arm will be followed through 30 days post procedure. There will be up to 15 participating study sites, with a minimum of five (5) sites, all located in the United States. ;


Study Design


NCT number NCT05554471
Study type Interventional
Source Cordis Corporation
Contact
Status Completed
Phase N/A
Start date August 30, 2022
Completion date July 11, 2023